The Multiple Sclerosis Association of America (MSAA) is proud to announce a new Chief Medical Officer (CMO) for the organization. Barry A. Hendin, a highly accomplished neurologist who specializes in MS, has assumed the role. Preceding Dr. Hendin was Jack Burks, MD, a clinical professor of neurology for the Herbert Wertheim College of Medicine at […]

The effort to enhance the lives and health of people with multiple sclerosis (MS) is advancing on many fronts, as researchers explore the impact of approaches ranging from stress management, exercise, diet, stem-cell therapy, and cannabis use, to a variety of approved and investigational disease-modifying therapies (DMTs).

This latest edition of “What’s New in MS Research” features highlights from the annual meetings of the American Academy of Neurology (AAN) and the Consortium of Multiple Sclerosis Centers (CMSC), both held in May of this year.

The Multiple Sclerosis Association of America’s (MSAA) free online support forum, My MSAA Community, has been a continued source of support, encouragement, and hope for members of the multiple sclerosis (MS) community since the Summer of 2016. Powered by HealthUnlocked, My MSAA Community was created to offer people with multiple sclerosis, care partners, friends, and family members a way to connect with others also affected by the condition.

The Multiple Sclerosis Association of America (MSAA) in partnership with @Point of Care, is proud to announce a new video series titled “Understanding Multiple Sclerosis.” This 12-part video series, featuring expert neurologist Dr. Michelle Fabian, provides an overview of the MS process, possible causes, symptoms, treatments, wellness strategies, and more. Each video offers valuable insights and up-to-date information in a relaxed, conversational style that is easy to understand and follow.

In a news release dated March 29, 2019, the United States Food and Drug Administration (FDA) announced the approval of Mavenclad® (cladribine) oral tablets to treat adults with relapsing forms of multiple sclerosis (MS). The approval is for individuals with relapsing-remitting MS (RRMS) and for individuals with active secondary-progressive MS (SPMS).

In a news release dated March 26, 2019, the United States Food and Drug Administration (FDA) announced the approval of Mayzent® (siponimod) oral tablets to treat adults with relapsing forms of multiple sclerosis (MS). The approval includes individuals with clinically isolated syndrome, relapsing-remitting MS (RRMS), and active secondary-progressive MS (SPMS). Mayzent is the only disease-modifying […]

The opening months of 2019 saw significant research advances on many fronts in multiple sclerosis (MS). A sophisticated analysis of data using healthcare claims found that the number of people in the United States living with MS is more than twice as high as previously estimated. Dietary studies sounded a cautionary note for people with MS drinking soda and many other sweetened beverages, and a hopeful note on the potential for flavonoid-rich cocoa to reduce MS-associated fatigue. A promising stem-cell therapy is moving forward in the clinical-trials process, while the FDA is considering whether to approve a new disease-modifying therapy (DMT).